Lannett Co. has launched a trio of new generic drug products recently approved by the Food and Drug Administration.


Lannett, diethylpropion tablets, phentermine HCI capsules, loxapine capsules, appetite suppressants, antipsychotic medication, obesity, generic drug, generic medications, Arthur Bedrosian, obesity treatment, schizophrenia


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Lannett ships three new generics

October 17th, 2011

PHILADELPHIA – Lannett Co. has launched a trio of new generic drug products recently approved by the Food and Drug Administration.

The new generic medications include two appetite suppressants — diethylpropion tablets (25 mg) and phentermine HCI capsules (37.5 mg) — and loxapine capsules (5 mg, 10 mg, 25 mg and 50 mg), an antipsychotic medication.

Diethylpropion and phentermine typically are used to treat obesity along with diet and exercise. However, phentermine is prescribed as an obesity treatment for people with such risk factors as high blood pressure, high cholesterol or diabetes. Loxapine is used to treat schizophrenia.

"Sales of the three products augment and strengthen our growing product offering, and we expect will be solid contributors to both sales and profits in fiscal 2012," Arthur Bedrosian, president and chief executive officer of Lannett, said in a statement.

Advertisement